GLP-1RA治疗儿童和青少年2型糖尿病及肥胖症的研究进展

Research progress on clinical application and safety of GLP-1RA in children and teenagers with type 2 diabetes and obesity

近年来,我国儿童和青少年2型糖尿病(T2DM)及肥胖发病率逐年升高。然而,目前国内批准用于治疗儿童和青少年T2DM及肥胖的药物有限,且失败率较高。近年来的研究表明,胰高血糖素样肽-1受体激动剂(GLP-1RA)对儿童和青少年T2DM及肥胖患者降糖和减重是有效且短期应用安全性较好,但处于生长发育期的儿童和青少年对GLP-1RA的反应和耐受程度不同于成人,胃肠道不良反应及低血糖发生率明显增高,故需要重视其长期使用的安全性问题,进一步开展更加系统的研究及长期随访评估。

In recent years,the incidence rate of type 2 diabetes(T2DM) and obesity in children and teenagers in China is increasing year by year.However,currently there are limited drugs approved domestically for the treatment of T2DM and obesity in children and teenagers,and the failure rate is high.In recent years,studies have shown that glucagon like peptide-1 receptor agonists(GLP-1RA) are effective and have good short-term safety in lowering blood sugar and weight loss in children and teenagers with T2DM and obese patients.However,children and teenagers in the growth and development stage have different reactions and tolerance levels to GLP-1RA compared to adults,and the incidence of gastrointestinal adverse reactions and hypoglycemia is significantly increased.Therefore,it is necessary to pay attention to the safety of their long-term use,and more systematic research and long-term follow-up evaluation should be further conducted.